Cargando…

MON-465 Novel Thyroid Hormone β Mutation L266s Causes Atrial Fibrillation & Cerebral Infarction

Background: Resistance against thyroid hormone β (RTHβ) is characterized by reduced tissue sensitivity to thyroid hormone. Patients with RTHβ resistance typically demonstrate increases in FT3 and FT4 accompanied by inappropriately elevated TSH. Mutations in the TRβ gene are the most common genetic d...

Descripción completa

Detalles Bibliográficos
Autores principales: Ono, Wataru, Kameda, Hiraku, Iesaka, Hiroshi, Izumihara, Satomi, Oe, Yuki, Kamigaki, Risa, Chiba, Koki, Kameda, Rena, Nomoto, Hiroshi, Cho, Kyu Yong, Nakamura, Akinobu, hayashi, Yoshitaka, Hideaki, Miyoshi, Atsumi, Tatsuya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7209217/
http://dx.doi.org/10.1210/jendso/bvaa046.399
_version_ 1783531023658647552
author Ono, Wataru
Kameda, Hiraku
Iesaka, Hiroshi
Izumihara, Satomi
Oe, Yuki
Kamigaki, Risa
Chiba, Koki
Kameda, Rena
Nomoto, Hiroshi
Cho, Kyu Yong
Nakamura, Akinobu
hayashi, Yoshitaka
Hideaki, Miyoshi
Atsumi, Tatsuya
author_facet Ono, Wataru
Kameda, Hiraku
Iesaka, Hiroshi
Izumihara, Satomi
Oe, Yuki
Kamigaki, Risa
Chiba, Koki
Kameda, Rena
Nomoto, Hiroshi
Cho, Kyu Yong
Nakamura, Akinobu
hayashi, Yoshitaka
Hideaki, Miyoshi
Atsumi, Tatsuya
author_sort Ono, Wataru
collection PubMed
description Background: Resistance against thyroid hormone β (RTHβ) is characterized by reduced tissue sensitivity to thyroid hormone. Patients with RTHβ resistance typically demonstrate increases in FT3 and FT4 accompanied by inappropriately elevated TSH. Mutations in the TRβ gene are the most common genetic disorder in thyroid hormone resistance and result in impaired thyroid receptor functions due to a dominant negative effect. Here, we describe a case with a novel TRβ mutation, presenting atrial fibrillation and cerebral infarction. Clinical case: A 55-year-old man presented chronic atrial fibrillation and tachycardia as the onset of cerebral infarction. Because blood tests revealed 5.6 pg/ml FT3 (reference range: 2.36–4.06), 3.39 ng/ml FT4 (0.71–1.5), 0.98 TSH μIU/ml (0.541–4.261), and negative TRAb, suggesting inappropriate secretion of TSH (SITSH). He was referred to our department for further investigation. All three test kits, including LUMIPULSE, ECLusys, and TOSOH, showed an unsuppressed TSH value despite hyperthyroxinemia, demonstrating genuine SITSH. His family history was unclear, but his father had died of heart disease. A pituitary MRI suggested microadenoma, but TSH-secreting pituitary adenoma was excluded because of a negative α subunit and responsiveness to a TRH stimulation test. The TRβ gene was analyzed with informed consent from the patient, and a novel mutation replacing the 266(th) amino acid serine (TCG) with leucine (TTG) in the 8(th) exon was found, confirming the diagnosis of RTHβ. Tachycardia and atrial fibrillation were considered to be caused by thyrotoxicosis in heart, which dominantly expresses TRα rather than TRβ. Therefore, β-blockers and anticoagulants, were continued. Conclusion: This is the first report of a case of RTHβ with the TRβ L266S mutation. This novel mutation is located in the thyroid hormone-binding area of the TRβ gene, suggesting that reduced hormone binding may cause thyroid hormone resistance.
format Online
Article
Text
id pubmed-7209217
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-72092172020-05-13 MON-465 Novel Thyroid Hormone β Mutation L266s Causes Atrial Fibrillation & Cerebral Infarction Ono, Wataru Kameda, Hiraku Iesaka, Hiroshi Izumihara, Satomi Oe, Yuki Kamigaki, Risa Chiba, Koki Kameda, Rena Nomoto, Hiroshi Cho, Kyu Yong Nakamura, Akinobu hayashi, Yoshitaka Hideaki, Miyoshi Atsumi, Tatsuya J Endocr Soc Thyroid Background: Resistance against thyroid hormone β (RTHβ) is characterized by reduced tissue sensitivity to thyroid hormone. Patients with RTHβ resistance typically demonstrate increases in FT3 and FT4 accompanied by inappropriately elevated TSH. Mutations in the TRβ gene are the most common genetic disorder in thyroid hormone resistance and result in impaired thyroid receptor functions due to a dominant negative effect. Here, we describe a case with a novel TRβ mutation, presenting atrial fibrillation and cerebral infarction. Clinical case: A 55-year-old man presented chronic atrial fibrillation and tachycardia as the onset of cerebral infarction. Because blood tests revealed 5.6 pg/ml FT3 (reference range: 2.36–4.06), 3.39 ng/ml FT4 (0.71–1.5), 0.98 TSH μIU/ml (0.541–4.261), and negative TRAb, suggesting inappropriate secretion of TSH (SITSH). He was referred to our department for further investigation. All three test kits, including LUMIPULSE, ECLusys, and TOSOH, showed an unsuppressed TSH value despite hyperthyroxinemia, demonstrating genuine SITSH. His family history was unclear, but his father had died of heart disease. A pituitary MRI suggested microadenoma, but TSH-secreting pituitary adenoma was excluded because of a negative α subunit and responsiveness to a TRH stimulation test. The TRβ gene was analyzed with informed consent from the patient, and a novel mutation replacing the 266(th) amino acid serine (TCG) with leucine (TTG) in the 8(th) exon was found, confirming the diagnosis of RTHβ. Tachycardia and atrial fibrillation were considered to be caused by thyrotoxicosis in heart, which dominantly expresses TRα rather than TRβ. Therefore, β-blockers and anticoagulants, were continued. Conclusion: This is the first report of a case of RTHβ with the TRβ L266S mutation. This novel mutation is located in the thyroid hormone-binding area of the TRβ gene, suggesting that reduced hormone binding may cause thyroid hormone resistance. Oxford University Press 2020-05-08 /pmc/articles/PMC7209217/ http://dx.doi.org/10.1210/jendso/bvaa046.399 Text en © Endocrine Society 2020. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Thyroid
Ono, Wataru
Kameda, Hiraku
Iesaka, Hiroshi
Izumihara, Satomi
Oe, Yuki
Kamigaki, Risa
Chiba, Koki
Kameda, Rena
Nomoto, Hiroshi
Cho, Kyu Yong
Nakamura, Akinobu
hayashi, Yoshitaka
Hideaki, Miyoshi
Atsumi, Tatsuya
MON-465 Novel Thyroid Hormone β Mutation L266s Causes Atrial Fibrillation & Cerebral Infarction
title MON-465 Novel Thyroid Hormone β Mutation L266s Causes Atrial Fibrillation & Cerebral Infarction
title_full MON-465 Novel Thyroid Hormone β Mutation L266s Causes Atrial Fibrillation & Cerebral Infarction
title_fullStr MON-465 Novel Thyroid Hormone β Mutation L266s Causes Atrial Fibrillation & Cerebral Infarction
title_full_unstemmed MON-465 Novel Thyroid Hormone β Mutation L266s Causes Atrial Fibrillation & Cerebral Infarction
title_short MON-465 Novel Thyroid Hormone β Mutation L266s Causes Atrial Fibrillation & Cerebral Infarction
title_sort mon-465 novel thyroid hormone β mutation l266s causes atrial fibrillation & cerebral infarction
topic Thyroid
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7209217/
http://dx.doi.org/10.1210/jendso/bvaa046.399
work_keys_str_mv AT onowataru mon465novelthyroidhormonebmutationl266scausesatrialfibrillationcerebralinfarction
AT kamedahiraku mon465novelthyroidhormonebmutationl266scausesatrialfibrillationcerebralinfarction
AT iesakahiroshi mon465novelthyroidhormonebmutationl266scausesatrialfibrillationcerebralinfarction
AT izumiharasatomi mon465novelthyroidhormonebmutationl266scausesatrialfibrillationcerebralinfarction
AT oeyuki mon465novelthyroidhormonebmutationl266scausesatrialfibrillationcerebralinfarction
AT kamigakirisa mon465novelthyroidhormonebmutationl266scausesatrialfibrillationcerebralinfarction
AT chibakoki mon465novelthyroidhormonebmutationl266scausesatrialfibrillationcerebralinfarction
AT kamedarena mon465novelthyroidhormonebmutationl266scausesatrialfibrillationcerebralinfarction
AT nomotohiroshi mon465novelthyroidhormonebmutationl266scausesatrialfibrillationcerebralinfarction
AT chokyuyong mon465novelthyroidhormonebmutationl266scausesatrialfibrillationcerebralinfarction
AT nakamuraakinobu mon465novelthyroidhormonebmutationl266scausesatrialfibrillationcerebralinfarction
AT hayashiyoshitaka mon465novelthyroidhormonebmutationl266scausesatrialfibrillationcerebralinfarction
AT hideakimiyoshi mon465novelthyroidhormonebmutationl266scausesatrialfibrillationcerebralinfarction
AT atsumitatsuya mon465novelthyroidhormonebmutationl266scausesatrialfibrillationcerebralinfarction